Pneumococcal vaccine is a Subunit Vaccine owned by CanSino Biologics, and is involved in 3 clinical trials, of which 1 was completed, and 2 are planned.

Protein-based pneumococcal vaccine elicits antibacterial property. Vaccine induces both cell mediated and humoral immunity which stimulates the production of B cells and T cells which leads to generation of the immune responses.

The revenue for Pneumococcal vaccine is expected to reach a total of $18m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Pneumococcal vaccine NPV Report.

Pneumococcal vaccine is originated and owned by CanSino Biologics.

Pneumococcal vaccine Overview

Protein-based pneumococcal vaccine is under development for the prevention of streptococcal pneumonia infections. The therapeutic candidate is a serotype-independent protein-based pneumococcal vaccine. It is administered through intramuscular route.

CanSino Biologics Overview

CanSino Biologics is a biopharmaceutical company that develops, manufactures and commercializes pneumococcal, polyvalent conjugate and adenovirus-based recombinant TB vaccines. The company is investigating Ad5-EBOV, an adenovirus type 5 vector, to treat Ebola virus; MCV2 and MCV4 vaccines for the prevention of Neisseria meningitidis bacteria. It is also evaluating DTcP vaccine against pertussis caused after primary vaccination in infants and children; and PBPV, PCV13i vaccines, targeting pneumococcal diseases. CanSino Biologics utilizes Adenovirus-based viral vector vaccine, conjugation, formulation, and protein structure design and recombinant technology to develop vaccines. It works in partnership with MC Master University, National Research Council of Canada and Beijing Institute of Biotechnology. CanSino Biologics is headquartered in Tianjin, China.

The company reported revenues of (Renminbi) CNY4,299.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CNY18.5 million in FY2020. The operating profit of the company was CNY1,911.6 million in FY2021, compared to an operating loss of CNY400.9 million in FY2020. The net profit of the company was CNY1,914.4 million in FY2021, compared to a net loss of CNY396.6 million in FY2020.

Quick View – Pneumococcal vaccine

Report Segments
  • Innovator
Drug Name
  • Pneumococcal vaccine
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.